wayground logo

Free Printable Worksheets

NEW

Font size

S
M
L
XL
Worksheets

P-Economic Quiz

Total questions: 20

Worksheet time: 30secs

Name
Class
Date
1.

CBA is the most common type of p-economic study in pharmacy literature

a)

True

b)

False

2.

The measurement unit for CUA is

a)

Monetary Unit

b)

Natural units

c)

QALY

d)

Perfect life

3.

With CBA, indirect costs are measured using _____, while intangible costs are measure using _____.

a)

IRR, human capital approach

b)

IRR, WTP approach

c)

human capital approach, WTP

d)

WTP, IRR

4.

If you see the term 'efficacy' used in a CEA, this means the drug can work under _____ conditions.

a)

real world

b)

relatively ideal

c)

Both a & b

d)

None

5.

If numbers are from the past, they need to be ______. If numbers are projected in the future, they need to be ______.

a)

discounted, adjusted

b)

counted, adjusted

c)

adjusted, discounted

d)

None

6.

An analysis is performed on the economic benefit of a pharmacist-led smoking-cessation programme. Data is extrapolated for the next 11 months. It should be dicounted/adjusted.

a)

True

b)

False

7.

This is used by drug companies to determine market potential, it determines total economic burden, an there is no agreement or standard method of conducting.

a)

CUA

b)

CBA

c)

COI

d)

Cost consequence

e)

Cost avoidance

8.

A Utility Rate (QOL) of 1 means

a)

coma

b)

death

c)

perfect health

d)

living being

9.

This compare costs for alternatives that are assumed to have equivalent outcomes. It is the simplest to conduct.

a)

CBA

b)

CUA

c)

CEA

d)

CMA

10.

Lost productivity ia a type of ______.

a)

direct medical

b)

indirect

c)

direct non-medical

d)

intangible

11.

Which of the following has the biggest advantage cost-effectiveness analysis has over other full economic evaluation techniques

a)

It can be used to compare different outcomes in a population

b)

It is the easiest to calculate and interpret

c)

It uses outcomes measured in natural units familiar to clinicians

d)

It can compare multiple outcomes at the same time

12.

Which of the following statements provides the best description of an incremental cost-effectiveness ratio?

a)

the extra cost to obtain an extra benefit realized from switching from one alternative to another

b)

a summary measurement of efficiency

c)

the cost per benefit of a new strategy, independent of other treatment alternatives

d)

the cost per quality-adjusted life years gained

13.

A full economic evaluation includes:

a)

a comparison of two or more alternatives in terms of costs and consequences

b)

an analysis of costs and consequences of one alternative

c)

an analysis of two or more alternatives in terms of consequences

d)

a comparison of two or more alternatives in terms of cost

14.

All of the following statements are general characteristics of cost effectiveness analyses (CEAs) except

a)

costs are measured in economic terms and the outcome is measured in natural units

b)

ratios of costs to effects are used to make judgments on cost effectiveness

c)

uses the human capital approach to place a dollar value on outcomes

d)

at least two drugs or therapeutic interventions are compared

15.

Which of the following statements can NOT describe a cost effective treatment alternative?

a)

a more expensive and less effective alternative

b)

a less expensive and less effective alternative

c)

a less expensive and more effective alternative

d)

a more expensive and more effective alternative

16.

In a cost benefit analysis, which of the following decision rules is correct and indicates a program should be implemented?

a)

net benefit < 0

b)

B/C > 1

c)

ICER > 1

d)

C/B > 1

17.

Which of the following is a disadvantage of conducting a cost benefit analysis (CBA)?

a)

a dollar value must be placed on health outcomes

b)

quality adjusted life years must be measured

c)

a comparison of the effects on different types of programs can be conducted

d)

outcomes must be measured in the same natural units

18.

Health is:

a)

a physical well being

b)

absence of disease

c)

being able to do what one wants

d)

all of the above

19.

A single item health related quality of life measure such as a pain scale has which of the following difficulties?

a)

the instrument is difficult to write and develop

b)

it is difficult to collect data

c)

the results are hard to interpret

d)

it is difficult for patients to answer

20.

Which of the following parameters is evaluated by a pharmacoeconomic analysis?

a)

Cost

b)

Outcomes

c)

Cost and outcomes

d)

side effects

e)

side effects and no needed to harm